103,500 Shares in UiPath Inc. (NYSE:PATH) Bought by Graphene Investments SAS

Graphene Investments SAS purchased a new stake in shares of UiPath Inc. (NYSE:PATH - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 103,500 shares of the healthcare company's stock, valued at approximately $2,571,000.

Several other large investors have also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its stake in UiPath by 792.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,089 shares of the healthcare company's stock valued at $52,000 after buying an additional 1,855 shares during the period. International Assets Investment Management LLC raised its stake in UiPath by 1,649.1% in the fourth quarter. International Assets Investment Management LLC now owns 177,358 shares of the healthcare company's stock valued at $4,406,000 after buying an additional 167,218 shares during the period. Bleakley Financial Group LLC raised its stake in UiPath by 4.9% in the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company's stock valued at $315,000 after buying an additional 598 shares during the period. 180 Wealth Advisors LLC raised its stake in UiPath by 0.3% in the fourth quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company's stock valued at $4,497,000 after buying an additional 492 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in UiPath by 2.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301,413 shares of the healthcare company's stock valued at $131,687,000 after buying an additional 119,782 shares during the period. 62.50% of the stock is owned by institutional investors and hedge funds.

UiPath Stock Up 0.7 %

Shares of PATH stock traded up $0.15 during trading hours on Tuesday, reaching $21.80. The company's stock had a trading volume of 5,856,769 shares, compared to its average volume of 9,218,472. The firm's 50 day simple moving average is $23.42 and its 200-day simple moving average is $21.33. The company has a market capitalization of $12.40 billion, a price-to-earnings ratio of -128.24 and a beta of 0.96. UiPath Inc. has a fifty-two week low of $12.38 and a fifty-two week high of $27.87.

UiPath (NYSE:PATH - Get Free Report) last issued its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.10. The firm had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. Sell-side analysts predict that UiPath Inc. will post -0.04 earnings per share for the current year.

Insider Buying and Selling at UiPath

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the firm's stock in a transaction on Monday, February 5th. The stock was sold at an average price of $22.47, for a total value of $359,520.00. Following the sale, the chief financial officer now owns 103,505 shares of the company's stock, valued at approximately $2,325,757.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 72,000 shares of company stock valued at $1,591,360. 31.03% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PATH. Needham & Company LLC restated a "buy" rating and issued a $30.00 price objective on shares of UiPath in a research note on Wednesday, March 20th. Evercore ISI increased their target price on UiPath from $24.00 to $27.00 and gave the stock an "in-line" rating in a research note on Thursday, March 14th. BMO Capital Markets increased their target price on UiPath from $24.00 to $28.00 and gave the stock a "market perform" rating in a research note on Thursday, March 14th. Wells Fargo & Company increased their target price on UiPath from $24.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Thursday, March 14th. Finally, Barclays increased their target price on UiPath from $23.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Friday, March 15th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $27.41.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.